Faropenem

Drug Profile

Faropenem

Alternative Names: ALP 201; BLA 857; Farom; Faropenem sodium; Fropenem; FRPM; RU 67655; SUN 5555; SY 5555; WY 49605; YM 044

Latest Information Update: 01 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Asubio Pharma
  • Developer Maruho
  • Class Antibacterials; Beta-lactams; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bacterial infections
  • Clinical Phase Unknown Otitis media

Most Recent Events

  • 31 Mar 2015 Maruho and Banbuntane Hotokukai Hospital complete a clinical pharmacokinetics trial in Otitis media (Chronic) in Japan (PO) (UMIN000014510)
  • 16 Sep 2005 Daiichi Suntory Pharma has been acquired by Daiichi Pharmaceutical
  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top